标题
Azacitidine
作者
关键词
-
出版物
DRUGS
Volume 72, Issue 8, Pages 1111-1136
出版商
Springer Nature
发表日期
2012-05-10
DOI
10.2165/11209430-000000000-00000
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
- (2015) Oncotarget
- MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
- (2012) M. Breccia et al. HAEMATOLOGICA
- Azacitidine adverse effects in patients with myelodysplastic syndromes
- (2011) L. San Miguel Amigo et al. ADVANCES IN THERAPY
- Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management
- (2011) Guillermo Garcia-Manero AMERICAN JOURNAL OF HEMATOLOGY
- Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p
- (2011) Lieke H. van der Helm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Azacitidine for the treatment of patients with acute myeloid leukemia
- (2011) Luca Maurillo et al. CANCER
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
- (2011) Toshiki Uchida et al. CANCER SCIENCE
- Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine
- (2011) Shane A. Gangatharan et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
- (2011) Huong Thi Thanh Tran et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
- (2011) U Platzbecker et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
- (2011) Haifa K. Al-Ali et al. LEUKEMIA & LYMPHOMA
- 177 UK experience of azacitidine therapy in patients with myelodysplastic syndromes
- (2011) S. Killick et al. LEUKEMIA RESEARCH
- 175 Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patients
- (2011) A. Jonasova et al. LEUKEMIA RESEARCH
- 82 Favourable outcome of young patient with t-MDS secondary to breast cancer treatment using azacitidine as induction therapy before allo-BMT
- (2011) G. Binotto et al. LEUKEMIA RESEARCH
- 102 Azacytidine as a bridge to haploidentical bone marrow transplant in a patient with hypocellular myelodysplasia with monosomy 7
- (2011) S.K. Rana et al. LEUKEMIA RESEARCH
- 286 The presence of aberrant myeloid progenitors predicts overall survival in intermediate-2 and high risk myelodysplastic syndromes upon treatment with azacitidine
- (2011) C. Alhan et al. LEUKEMIA RESEARCH
- 317 Influence of mild bone marrow fibrosis on response of int-2/high risk MDS patients to 5-azacitidine
- (2011) A. Sanna et al. LEUKEMIA RESEARCH
- Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
- (2011) Sabine Hagemann et al. PLoS One
- Treatment of Higher-Risk Myelodysplastic Syndrome
- (2011) Guillermo Garcia-Manero SEMINARS IN ONCOLOGY
- Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
- (2010) Katharina Götze et al. ANNALS OF HEMATOLOGY
- Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment
- (2010) Joon Ho Moon et al. ANNALS OF HEMATOLOGY
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
- (2010) O. Goodyear et al. BLOOD
- Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
- (2010) Bart L. Scott et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
- (2010) Pierre Fenaux et al. BRITISH JOURNAL OF HAEMATOLOGY
- Azacitidine for the treatment of lower risk myelodysplastic syndromes
- (2010) Pellegrino Musto et al. CANCER
- Activity of azacitidine in chronic myelomonocytic leukemia
- (2010) Rubens Costa et al. CANCER
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
- (2010) Elias Jabbour et al. CANCER
- In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
- (2010) Yong Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency
- (2010) G. Nicolas Batty et al. Clinical Lymphoma Myeloma & Leukemia
- Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
- (2010) John F. Seymour et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase I biological study of azacitidine (VidazaTM) to determine the optimal dose to inhibit DNA methylation
- (2010) Ilan Bernstein et al. Epigenetics
- Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
- (2010) M. G. Della Porta et al. HAEMATOLOGICA
- Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
- (2010) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes
- (2010) M Y Follo et al. LEUKEMIA
- Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
- (2010) Pierre Fenaux et al. LEUKEMIA RESEARCH
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Safety and efficacy of azacitidine in myelodysplastic syndromes
- (2010) Carlos Vigil et al. Drug Design Development and Therapy
- A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
- (2009) Mike G. Martin et al. AMERICAN JOURNAL OF HEMATOLOGY
- How I treat patients with myelodysplastic syndromes
- (2009) R. M. Stone BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
- (2009) M. E. Figueroa et al. BLOOD
- 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
- (2009) T Field et al. BONE MARROW TRANSPLANTATION
- Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
- (2009) M. T. Voso et al. CLINICAL CANCER RESEARCH
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
- (2009) Roger M. Lyons et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
- (2009) C Flotho et al. LEUKEMIA
- Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
- (2009) M. Y. Follo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myelodysplastic syndromes
- (2008) S. D. Nimer BLOOD
- Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
- (2008) T. Qin et al. BLOOD
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
- (2008) Y. Jiang et al. BLOOD
- Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cells
- (2008) Rasheed Khan et al. EXPERIMENTAL HEMATOLOGY
- Myelodysplastic syndromes: biology and treatment
- (2008) M. Jädersten et al. JOURNAL OF INTERNAL MEDICINE
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now